tradingkey.logo
tradingkey.logo
Search

GSK plc

GSK
Add to Watchlist
52.500USD
+0.600+1.16%
Close 06/26, 16:00ETQuotes delayed by 15 min
105.93BMarket Cap
13.53P/E TTM

More Details of GSK plc Company

GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.

GSK plc Info

Ticker SymbolGSK
Company nameGSK plc
IPO dateMay 22, 1972
CEOWaterhouse (Deborah)
Number of employees68629
Security typeDepository Receipt
Fiscal year-endMay 22
Address980 Great West Road
CityBRENTFORD
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited Kingdom
Postal codeTW8 9GS
Phone442080475000
Websitehttps://www.gsk.com/
Ticker SymbolGSK
IPO dateMay 22, 1972
CEOWaterhouse (Deborah)

Company Executives of GSK plc

Name
Name/Position
Position
Shareholding
Change
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.23K
+0.01%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
43.08K
+4.31%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
4.24K
+18.60%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.80K
+28.62%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--
Ms. Victoria Anne Whyte
Ms. Victoria Anne Whyte
Company Secretary
Company Secretary
--
--
Mr. Phil C. Thomson
Mr. Phil C. Thomson
President - Global Affairs
President - Global Affairs
--
--
Dame Emma N. Walmsley
Dame Emma N. Walmsley
Chief Executive Officer, Executive Director
Chief Executive Officer, Executive Director
--
--
Mr. Luke Miels
Mr. Luke Miels
Chief Executive Officer - Designate, Director
Chief Executive Officer - Designate, Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. Hal V. Barron, M.D.
Dr. Hal V. Barron, M.D.
Non-Executive Director
Non-Executive Director
602.23K
+0.01%
Ms. Shobie Ramakrishnan
Ms. Shobie Ramakrishnan
Chief Digital and Technology Officer
Chief Digital and Technology Officer
514.11K
+0.12%
Mr. Charles A. (Charlie) Bancroft
Mr. Charles A. (Charlie) Bancroft
Senior Independent Non-Executive Director
Senior Independent Non-Executive Director
43.08K
+4.31%
Ms. Elizabeth McKee (Liz) Anderson
Ms. Elizabeth McKee (Liz) Anderson
Independent Non-Executive Director
Independent Non-Executive Director
4.24K
+18.60%
Dr. Jeannie Lee
Dr. Jeannie Lee
Independent Non-Executive Director and Scientific & Medical Expert
Independent Non-Executive Director and Scientific & Medical Expert
2.80K
+28.62%
Mr. David S. Redfern
Mr. David S. Redfern
President - Corporate Development
President - Corporate Development
--
--

FAQs

Who are the top five shareholders of GSK plc?

The top five shareholders of GSK plc are: Dr. Hal V. Barron, M.D.

How many institutions hold shares of GSK plc (GSK)?

As of 2026Q1, 1585 institutions hold shares of GSK plc, with a combined market value of approximately 393.46M, accounting for 19.40% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -23489904.00.

What is the biggest source of revenue for GSK plc?

In 2026Q1, the HIV business generated the highest revenue for GSK plc, amounting to 10.12B and accounting for 23.53% of total revenue.
KeyAI